ABC Update from ACC 2016:
New Heart Failure Data from Paradigm HF
A new post-hoc analyses of the PARADIGM-HF trial was presented at the American College of Cardiology Scientific Sessions in Chicago. The updated data noted reduced CV death or hospitalization for HF after treatment with sacubitril and valsartan in patients with HF with reduced ejection fraction regardless of prior HF hospital admissions or background therapy.
PARADIGM-HF was a well-received trial of sacubitril/valsartan (Entresto, Novartis) compared with the ACE inhibitor enalapril.
The recent analysis demonstrated that sacubitril/valsartan benefited multiple patient types patients. The positive outcomes were seen in HF patients who were clinically stable and those who were the least stable, with HF hospitalization within the previous 3 months. Importantly, sacubitril/valsartan was associated with at least a 20% greater reduction in CV death or HF hospitalization compared to a standard ACE inhibitor, enalapril.
In addition,regardless of background therapy, sacubitril/valsartan was beneficial with HFrEF and reduced the risk for CV death or HF hospitalization by approximately 20% compared with enalapril. Among patients with benefit included the following: taking higher and lower doses of beta-blockers, those taking mineralocorticoid receptor antagonists and those with or without an ICD or CRT-D.